Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Gastroenterology
Published in: Indian Journal of Gastroenterology 6/2014

01-11-2014 | Case Series

Olmesartan-related sprue-like enteropathy

Authors: Naresh Bhat, N. K. Anupama, Amit Yelsangikar, Kayal Vizhi

Published in: Indian Journal of Gastroenterology | Issue 6/2014

Login to get access

Abstract

Chronic diarrhea is a common clinical problem in gastroenterology practice and often difficult to diagnose the cause. Presence of villous atrophy in these subjects is not specific as differential diagnosis can be broad. Drug-induced diarrhea is often overlooked during the evaluation. We report a short series of such challenging small bowel diarrhea secondary to olmesartan-related sprue-like enteropathy.
Literature
1.
Farrell RJ, Kelly CP. Celiac sprue and refractory sprue. In: Farrell RJ, Kelly CP, editors. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease, 9th edition. Philadelphia: Saunders- Elsevier; 2010. p. 1797–820.
2.
De Gaetani M, Tennyson CA, Lebwohl B, et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108:647–53.CrossRef
3.
Ludvigsson JF, Brandt L, Montgomery SM, et al. Validation of villous atrophy and small intestinal inflammation in Swedish biopsy registers. BMC Gastroenterol. 2009;9:19.PubMedCentralPubMedCrossRef
4.
Zielger TR, Fernandez-Estivariz C, Gu LH, et al. Severe villous trophy and chronic malabsorption induced by azathioprine. Gastroenterology. 2003;124:1950–7.CrossRef
5.
Kamar N, Faure P, Dupuis E, et al. Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl Int. 2004;17:463–7.PubMedCrossRef
6.
Weclawiak H, Ould-Mohamed A, Bournet B, et al. Duodenal villous atrophy after solid-organ transplantation. Am J Transplant. 2011;11:575–82.PubMedCrossRef
7.
8.
Nielson JA, Steephen A, Lewin M. Angiotensin–II inhibitor (olmesartan) induced collagenous sprue with resolution following discontinuation of drug. World J Gastroenterol. 2013;19:6928–30.CrossRef
9.
Ianiro G, Bibbo S, Montalto M, et al. Systematic review: sprue like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40:16–23.PubMedCrossRef
Metadata
Title
Olmesartan-related sprue-like enteropathy
Authors
Naresh Bhat
N. K. Anupama
Amit Yelsangikar
Kayal Vizhi
Publication date
01-11-2014
Publisher
Springer India
Published in
Indian Journal of Gastroenterology / Issue 6/2014
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-014-0506-7

Other articles of this Issue 6/2014

Indian Journal of Gastroenterology 6/2014 Go to the issue

LETTER

Retrospective analysis of operated cases of post appendectomy small bowel obstruction in a tertiary care centre

Letter

Nonalcoholic fatty liver disease among potential live liver donors—A preliminary experience from Sri Lanka

IMAGE

An unusual cause of chronic diarrhea

Original Article

Does leptospirosis behave adversely in cirrhosis of the liver?

Original Article

Air cholangiogram is not inferior to dye cholangiogram for malignant hilar biliary obstruction: A randomized study of efficacy and safety

OBITUARY

Professor Hiralal Gulabhai Desai (1933–2014)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits